Expert Systems and Eilean Therapeutics Launch First Clinical Trial of Balamenib, a Promising Menin Inhibitor

AI-driven drug discovery firm Expert Systems has reached a key milestone with its partner, Eilean Therapeutics, by initiating the first phase of clinical trials for balamenib (ZE63-0302), a targeted menin-KMT2A inhibitor. The trial is conducted under the Australian TGA's CTN program. Bill Farley, Expert Systems' Chief Business Officer, highlighted balamenib's superior pre-clinical profile, emphasizing its safety, tolerability, and suitability for outpatient use, which are significant over other drugs in its class. The development of balamenib was expedited through Expert Systems' advanced AI platform.
Eilean Therapeutics, backed by Orbimed, Torrey Pines Investment, and Dr. John C. Byrd, is focused on developing innovative treatments for various cancers, utilizing Expert Systems' AI technology to enhance the efficiency of the drug discovery and development process.
Balamenib, an oral medication, has shown potent inhibition of menin in both cell line and xenograft model studies. It is particularly effective when combined with eiletoclax and lomonitinib, drugs developed by Eilean Therapeutics targeting BCL-2 and pan FLT3/IRAK4 respectively. The drug has demonstrated a better safety profile, lacks QTc prolongation, and does not interact with cytochrome P450 3A4 metabolism. It also has a lower risk of resistance associated with menin "hot spot" mutations.
Expert Systems provides a full spectrum of preclinical drug discovery services, from target identification to toxicology, using a hybrid AI system that integrates proprietary and public databases. The company has played a significant role in the establishment and management of numerous R&D programs and startup companies.
Eilean Therapeutics is a biopharmaceutical company that collaborates with Orbimed, Torrey Pines Investment, and Dr. John C. Byrd to identify novel small molecule inhibitors for hematologic and solid cancers. The company uses Expert Systems' AI platform and its partners' data and expertise to design and develop advanced therapies, aiming to create new treatments for cancer patients.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!